Eagle pharmaceuticals announces receipt of delisting notification from nasdaq

Woodcliff lake, n.j., may 22, 2024 (globe newswire) -- eagle pharmaceuticals, inc. (nasdaq: egrx) (the “company” or “eagle”) today announced that it received a notice (the “notice”) on may 20, 2024, from the listing qualifications department (the “staff”) of the nasdaq stock market llc (“nasdaq”) advising the company that it has initiated a process to delist the company's securities from nasdaq because the company had not filed its form 10-q for the quarter ended september 30, 2023 (the “q3 2023 form 10-q”) and its form 10-k for the year ended december 31, 2023 (the “2023 form 10-k”) by may 13, 2024. the notice further advises the company that, pursuant to nasdaq listing rule 5810(d)(2), the company's failure to timely file its quarterly report on form 10-q for the quarter ended march 31, 2024 (the “q1 2024 form 10-q”) serves as an additional and separate basis for delisting.
NDAQ Ratings Summary
NDAQ Quant Ranking